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Abstract
The gold standard for a deﬁnitive diagnosis of Parkinson disease (PD) is the pathologic ﬁnding
of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid
into plaques and hyperphosphorylated tau into tangles. Implicit in this clinicopathologic-based
nosology is the assumption that pathologic protein aggregation at autopsy reﬂects pathogenesis
at disease onset. While these aggregates may in exceptional cases be on a causal pathway in
humans (e.g., aggregated α-synuclein in SNCA gene multiplication or aggregated β-amyloid in
APP mutations), their near universality at postmortem in sporadic PD and AD suggests they
may alternatively represent common outcomes from upstream mechanisms or compensatory
responses to cellular stress in order to delay cell death. These 3 conceptual frameworks of
protein aggregation (pathogenic, epiphenomenon, protective) are diﬃcult to resolve because of
the inability to probe brain tissue in real time. Whereas animal models, in which neither PD nor
AD occur in natural states, consistently support a pathogenic role of protein aggregation,
indirect evidence from human studies does not. We hypothesize that (1) current biomarkers of
protein aggregates may be relevant to common pathology but not to subgroup pathogenesis
and (2) disease-modifying treatments targeting oligomers or ﬁbrils might be futile or delete-
rious because these proteins are epiphenomena or protective in the human brain under mo-
lecular stress. Future precision medicine eﬀorts for molecular targeting of neurodegenerative
diseases may require analyses not anchored on current clinicopathologic criteria but instead on
biological signals generated from large deeply phenotyped aging populations or from smaller
but well-deﬁned genetic–molecular cohorts.
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A cognitive dissonance in research on biomarkers and disease-
modifying treatments for Parkinson disease (PD) and Alz-
heimer disease (AD) is the dual acceptance of 2 opposite
tenets: that their clinical heterogeneity reﬂects several diseases
subsumed within each and that we are on the verge of ﬁnding
the set of perfect biomarkers that will explain their collective
progression and response to therapy.1 Recent review articles
on biomarkers and precision medicine start with the standard
disclaimer that a major challenge is the existence of many
diseases included under PD and AD (e.g., “…trying to make
one drug work for all PD patients… is wrong because (1) PD
is not a single disease, and (2) no 2 individuals have the same
biological makeup”2), only to revert to traditional form by
reviewing or proposing analyses of a large set of clinical and
biological data collected on cohorts of clinically diagnosed
individuals to overcome heterogeneity.3 Enormous ﬁnancial
and logistical resources have been devoted to protein-based
biomarkers and anti-β-amyloid (Aβ) treatments with little
return on investment. Therefore, it is imperative to review the
disease framework on which biomarker development and the
design of disease-modifying therapies are anchored.
Protein aggregation as causal of
a single disease: Bradford
Hill assessment
Mutations in and multiplications of α-synuclein- and Aβ-
related genes cause certain forms of PD and AD in aﬀected
families with these genetic abnormalities.4,5 Overexpression
of these proteins coupled to excessive aggregations has been
clearly shown to cause neuronal dysfunction and death in
numerous models.6,7
To examine the causality of α-synuclein/Aβ/tau aggregation in
human sporadic PD/AD (i.e., without the point mutations or
gene multiplication in the families where protein aggregation is
assumed to be directly causal), we utilized the Bradford Hill
criteria for causality assessment.8,9 These are a set of 9 criteria
developed by Sir Austin BradfordHill to provide epidemiologic
evidence of a causal relationship between an apparent cause
and an observed eﬀect. We tested the current disease model
under which α-synuclein and Aβ/tau aggregations are thought
to be causal to PD and AD, respectively, by compiling all
the published evidence from studies on humans available and
categorizing it according to each of the criteria.
Search strategy and selection criteria
We conducted a search in MEDLINE and PubMed for articles
published until June 6, 2018, using the search terms “protein
aggregation,” “alpha synuclein,” “oligomers,” “ﬁbrils,” “amyloid,”
“senile plaque,” “phospho-tau,” “Lewy body,” “Parkinson dis-
ease,” “Alzheimer disease,” “biomarker,” and “pathology.”We
also searched references and ClinicalTrials.gov for relevant
studies. No language restrictions were applied. The ﬁnal ref-
erence list was generated on the basis of relevance to the topics
covered in this Hypothesis article.
We conducted a systematic review in accordance with the
Preferred Reporting Items for Systematic Reviews andMeta-
analyses (PRISMA) guidelines.10 Eligible epidemiologic, mo-
lecular (e.g., neuroinﬂammation, mitochondrial dysfunction,
oxidative stress, ubiquitin-proteasome system dysfunction, cal-
cium signaling dysregulation, autophagy dysfunction, synaptic
dysfunction, cholesterol metabolism alteration),11,12 pathologic,
autopsy, imaging, and interventional studies on α-synuclein, Aβ,
and tau were included. We excluded animal models and vascu-
lar dementia/parkinsonism studies. Electronic search of articles
published up to January 2018was conducted using theCochrane
Central Register of Controlled Trials (CENTRAL), EMBASE,
PubMed, and references from relevant articles. Search strategy
included free text and Medical Subject Headings (MeSH)
terms (table e-1, doi.org/10.5061/dryad.g1nq02r). No restric-
tions were applied to sex, language, or sample size. Titles and
abstracts of all studies identiﬁed were screened for inclusion
and exclusion criteria. Full-text studies of eligible articles
were obtained to conﬁrm eligibility and discard duplicates. A
data collection form was used to extract variables of interest
for the selected studies. Given the heterogeneity of study
designs, risk of bias of individual studies was appraised uti-
lizing the National Heart, Lung, and Blood Institute tools,13
following the Cochrane handbook recommendations.14 Stud-
ies with high risk of bias were excluded from further analysis.
Remaining studies underwent data extraction and BradfordHill
criteria–based classiﬁcation. These procedures were conducted
independently by 2 authors and disagreements were settled by
consensus among authors.
Out of the 1,194 records derived from the initial search strat-
egy, 54 studies15–24,e1–e41 met full search criteria (ﬁgure 1).
Three studiese42–e44 were classiﬁed as having high risk of bias
and were excluded from further analysis. Agreement was met
between evaluators in all cases. A total of 2 and 4 of the 9
Bradford Hill criteria supported causality for PD and AD,
respectively (tables 1 and e-2).8,9 Altogether, human studies
of protein aggregation in AD and PD do not meet a mini-
mum set of Bradford Hill’s criteria to support a causal role.
Although the absence of support for causality in the litera-
ture of protein aggregation in human studies does not es-
tablish absence of causality,25 these ﬁndings encourage the
examination of alternative pathogenic hypotheses in PD
and AD.
Glossary
Aβ = β-amyloid; AD = Alzheimer disease; DLB = dementia with Lewy bodies; PD = Parkinson disease.
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Current model of disease
and challenges
Ongoing work on biomarker development and disease-
modifying therapies is partly built on a model of protein
misfolding and subsequent aggregation as an initial process in
a cascade of subsequent, serial events held as causal to a single
disease. In PD, it is proposed that α-synuclein monomers
assemble into oligomers, which in turn give rise to α-synuclein
ﬁbrils, the earliest disease-causing abnormalities, and the major
protein contribution of Lewy bodies and Lewy neurites (ﬁgure 2,
upper panel).26 It is surmised that α-synuclein aggregation
leads to neuronal dysfunction, loss of connectivity, and neu-
ronal death. In AD, it is proposed that the amyloid precursor
protein cleavage product and hyperphosphorylated tau protein
aggregate into extracellular plaques and intracellular neuroﬁ-
brillary tangles, respectively.12 These plaques and tangles may
then elicit a variety of secondary metabolic and molecular
changes, which in turn lead to cellular dysfunction that (1)
perpetuates the formation of additional pathogenic protein
aggregates or (2) directly accelerates or magniﬁes the eﬀect
on cell death through these molecular changes (“kindling”
phenomenon)11 (ﬁgure 2, lower panel). Nevertheless, 3 main
arguments challenge these models.
First challenge: Uncertain temporality and
biological gradient
Unlike other ﬁelds in medicine, brain tissue is not readily
accessible for diagnostic or research purposes. Instead, re-
search endeavors have relied on specimens obtained from
2 sources: (1) extracranial sources (e.g., biopsies of skin,
salivary gland, gut; samples of blood and CSF) collected during
life and (2) the brain itself, harvested postmortem, many years
after events of interest have taken place. Even pathology studies
that include samples from patients with diﬀerent disease se-
verity or “stages” are inherently cross-sectional. In an attempt
to assess the temporality of pathologic events, AD biomarker-
to-autopsy validation studies have yielded extraordinary prog-
ress, with in vivo CSF sampling and PET imaging of Aβ/tau
now accepted as valid surrogates for protein brain deposition.27
These advances have led to 2 observations in AD: that Aβ and
tau, sequentially or concurrently, may be placed at the start of
a chain of events before the onset of cognitive dysfunction, at
what we assume to be time zero (see “Temporality” criteria in
tables 1 and e-2)15–17; and that the co-presence of Aβ and tau
leads to greater cognitive decline than either alone (see “Bi-
ological gradient” criteria in tables 1 and e-2 [doi.org/10.5061/
dryad.g1nq02r]).15,16 There is no corresponding neuroimaging
or CSF biomarker counterpart for idiopathic PD. While this in
vivo visualization has been assumed to represent time zero, it is
also plausible that disease pathogenesis begins before the ag-
gregation of proteins becomes detectable, rendering them as
intermediate rather than initiating events in the pathway to
cell death.
Second challenge: Incidental pathology,
copathology, and nonspecific pathology
Without the ability to serially examine living brain tissue for
potentially dynamic components in cellular proteostatic mech-
anisms, diseases are classiﬁed as proteinopathies (e.g., synu-
cleinopathy) based on protein aggregates as end products. For
synucleinopathies, for instance, this is the case in PD, multiple
system atrophy, and dementia with Lewy bodies (DLB), as
well as nonparkinsonian (peripheral) synucleinopathies, such
as pure autonomic failure, and atypical synucleinopathies, in-
cluding selected neurodegenerations with brain iron accumu-
lation such as mitochondrial membrane protein-associated
neurodegeneration,28 the parkinsonian lysosomal disorders
Kufor-Rakeb syndrome, Gaucher disease, andChediak-Higashi
syndrome, and the nonparkinsonian Sanﬁlippo syndrome.29,30
The α-synuclein ubiquity permeates into AD: Lewy body pa-
thology accumulates in over 50% of autopsy-proven ADbrains31
and, conversely, 77% of autopsy-proven PD dementia or DLB
cases exhibit ADpathology.32 Separately, the classic ADproteins
Aβ and tau-positive neuroﬁbrillary tangles have been re-
spectively reported in 13% and 48% of sporadic Creutzfeldt-
Jakob disease cases.24 Given their widespread appearance
in a variety of phenotypically diverse diseases, pathologies of
α-synuclein andAβ/taumay not be pathogenic (see “Speciﬁcity”
criteria in tables 1 and e-2 [doi.org/10.5061/dryad.g1nq02r]).
The term “incidental pathology” has been applied to the ﬁnding
of protein aggregation on postmortem studies of neurologically
normal individuals. In the framework of α-synuclein- and Aβ/
tau-based proteins as AD and PD “pathology,” it is often as-
sumed that, when found on autopsy, these might represent
prodromal individuals, on the road to clinical disease had they
Figure 1 Flow chart of study selection
CENTRAL = Central Register of Controlled Trials.
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lived long enough. However, supra-surviving individuals (the
over-90 or oldest-old) exhibit high frequency of AD pathology
without dementia (;50%)33,34 and PD pathology without
parkinsonism (;25%).35 Notably, no cognitive tests among
the oldest-old without dementia can predict AD neuropathol-
ogy within 3 years before death.36 In fact, neuropathology
studies in the oldest-old have either shown no correlation be-
tween premortem cognitive function and AD neuropathol-
ogy37 or even a paradoxical association between normal
cognition and increased AD neuropathology.38 The 90+ Study
(183 brain autopsies from individuals who died at or after the
age of 90 years) yielded robust support for an inverse re-
lationship between AD pathology and clinical dementia, even
beyond the simple observation that intermediate to high AD
pathology clusters similarly in people with (23%) and without
dementia (28%).39 Further analysis of the data suggests a pro-
tective eﬀect of AD pathology. Compared to non-AD pathol-
ogy (microinfarcts and white matter disease; dementia, n = 19;
no dementia, n = 6), AD pathology (dementia, n = 23; no
dementia, n = 24) was associated with a signiﬁcantly reduced
risk of dementia (odds ratio 0.3; 95% conﬁdence interval
0.1–0.9; p = 0.03; analysis not in the original publication).39
Therefore, it is plausible that these individuals may have lived
well beyond a normal lifespan without neurologic symptoms
because of, not despite, AD pathology. Under this framework,
Aβ and tau aggregation may have served as a mechanism to
compensate for active disease-causing biological abnormalities
(while minimizing the presumably toxic soluble ﬁbrils required
Table 1 Bradford Hill criteria applied to human studies of α-synuclein (α-syn) and β-amyloid (Aβ)/tau aggregation in
Parkinson disease (PD) and Alzheimer disease (AD)
Criteria definition PD AD
Strength α-Syn/Aβ/tau aggregation significantly
correlates with PD/AD using appropriate
methodology and accounting for confounding
factors
Supporting: 3e1–e3 Supporting: 10e4–e13
Opposing: 0 Opposing: 0
Conclusion: Support Conclusion: Support
Consistency
(replication)
Multiple studies using several locations,
populations, and methods show a consistent
correlation between α-syn/Aβ/tau aggregates
with PD/AD
Supporting: 3e1–e3 Supporting: 10e4–e13
Opposing: 0 Opposing: 0
Conclusion: Support Conclusion: Support
Temporality Cause preceding the effect: time interval
between α-syn/Aβ/tau aggregation ascertained
in vivo before symptom development in PD/AD
Supporting: No studies Supporting: 315–17
Opposing: No studies Opposing: 0
Conclusion: No support Conclusion: Support
Experiment Interventions targeted against α-syn/Aβ/tau
aggregates decrease PD/AD incidence, severity,
or rate of progression
Supporting: 0 Supporting: 0
Opposing: 0 Opposing: 7e14,18–23
Conclusion: No support Conclusion: No support
Biological
gradient
Dose-response curve between α-syn/Aβ/tau
aggregates concentration and PD/AD incidence,
severity, or rate of progression
Supporting: 0 Supporting: 5e15–e18,17
Opposing: 2e1,e2 Opposing: 0
Conclusion: No support Conclusion: Support
Plausibility α-Syn/Aβ/tau aggregates affect molecular
pathways associated with PD/AD
Supporting: 2e19,e20 Supporting: 5e22–e26
Opposing: 1e21 Opposing: 4e27–e30
Conclusion: Uncertain Conclusion: Equivocal
Analogy If α-syn/Aβ/tau aggregates cause PD/AD, similar
protein aggregations could also cause PD/AD
A pathologic definition of PD precludes
this analysis to avoid circular reasoning
A pathologic definition of AD precludes
this analysis to avoid circular reasoning
Specificity If α-syn/Aβ/tau aggregates cause PD/AD, these
proteins should not be present in diseases
other than PD/AD or healthy controls
Supporting: 0 Supporting: 0
Opposing: 10e31,e32,e34–e41 Opposing: 1024,e33–e41
Conclusion: No support Conclusion: No support
Coherence Cause–effect should be consistent across all
available evidence, without contradictions or
discrepancies
Supporting: 0 Supporting: 0
Opposing: 13e1,e2,e21,e31,e32,e34–e41 Opposing: 21e14,18−24,e27–e30,e33–e41
Conclusion: No support Conclusion: No support
Adapted from references 8, 9, and 25. Individual characteristics of supporting and opposing studies are supplied in table e-2 (doi.org/10.5061/dryad.g1nq02r).
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to form them), with clinical disease appearing after this
mechanism is overwhelmed (see “Speciﬁcity” criteria in tables 1
e-2 [doi.org/10.5061/dryad.g1nq02r]).
Third challenge: Experimental failure in anti-
amyloid therapies
Anti-amyloid therapies that target insoluble Aβ forms (e.g.,
AN1792, gantenerumab, bapineuzumab), soluble forms
(e.g., solanezumab), or prevent its formation (e.g., sem-
agacestat, γ-secretase inhibitor) have failed to produce
cognitive beneﬁts in AD.18–23 Some agents have been as-
sociated with adverse events (e.g., AN1792, aseptic me-
ningoencephalitis18; gantenerumab and bapineuzumab,
Aβ-related abnormalities19,20; semagacestat, skin cancer and
infections),21 possibly due to immunologic mechanisms (e.g.,
AN1792, T-cell response)18 or impaired protein processing
(e.g., semagacestat, Notch protein)21 in selected cases. Al-
though unsuccessful or insuﬃcient Aβ load reduction may
account for clinical futility, an issue that may be deﬁnitively
answered after the ongoing phase III aducanumab trial results
are reported (ClinicalTrials.gov Identiﬁer: NCT02477800),
one can argue that protein aggregation is not the culprit for cell
death (see “Experiment” criteria in tables 1 and e-2 [doi.org/10.
5061/dryad.g1nq02r]).
Alternative models of disease
If α-synuclein and Aβ/tau protein aggregation are not in
a direct causal pathway in PD and AD, they may still con-
tribute to neurodegeneration, or be an epiphenomenon, or
guard against toxic soluble forms of the proteins by seques-
tering them as innocuous insoluble forms. Each of these 3
hypothetical models may be inﬂuenced by lifelong exposure
to genetic and environmental factors that might contribute to
increased susceptibility, exhaustion of adaptive responses,
and, ultimately, cell dysfunction and death. We use α-synu-
clein to illustrate these alternative models (ﬁgure 3), but they
apply similarly to Aβ and tau protein aggregation.
Alternative model 1: Protein aggregation as
accelerator of pathology of multiple diseases
Aside from disorders where a genetic mutation causes initial
accumulation of α-synuclein (e.g., missense mutations and
multiplication of SNCA)4 or of Aβ (e.g., triplication of APP
Figure 2 Current model of protein aggregation in Parkinson disease (single disease model)
Abnormal soluble oligomers and fibrils of α-synuclein are directly pathogenic (upper panel). Alternatively or complementarily, secondarymolecular changes
created after protein aggregation combine with oligomers and fibrils to hasten cell death (lower panel). T-0 = time zero; α-syn = α-synuclein.
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in Down syndrome or amyloid precursor protein [APP] gene
mutations and duplication),5 in which these protein aggre-
gates are truly pathogenic, it is plausible that accumulation
of α-synuclein or of Aβ/tau enhances other primary patho-
genic molecular mechanisms of neurodegeneration in spo-
radic forms of PD and AD (ﬁgure 3A). Putatively, a prion-like
propagation of α-synuclein ﬁbrils between adjacent cells29 falls
into this category, without requiring that oligomers and ﬁbrils
act as the initial pathogenic event. This model accepts het-
erogeneous upstream pathogenic events, but relies on soluble
proteins (α-synuclein, Aβ) misfolding and aggregating, as
a convergent driver of cellular death. In this model, misfolded
variants of α-synuclein and Aβ are suitable for biomarker
development and therapeutic targeting.
Alternative model 2: Protein aggregation as
epiphenomena of multiple diseases
According to this model, a range of molecular abnormalities
lead to cells being unable to adequately degrade misfolded
proteins, which aggregate into α-synuclein ﬁbrils in Lewy
bodies (ﬁgure 3B; or from misfolded amyloid precursor
protein into misfolded oligomers, then ﬁbrils, then plaques in
AD). These protein aggregates become byproducts (common
denominators or epiphenomena) of several pathogenic
pathways, and themselves exert no pathogenic or protective
role. According to this model, diﬀerent underlying molecular
abnormalities remain pathogenic of diﬀerent molecular dis-
eases; their relationship to one another rests only in the type
of protein they cannot properly recycle.
Alternative model 3: Protein aggregation as
protective mechanism of multiple diseases
In this model, molecular abnormalities aﬀect the cellular
machinery that normally degrades proteins. These misfolded
proteins are sequestered into Lewy bodies as a mechanism to
promote maintenance of neuronal and synaptic function de-
spite coexistent and actively disrupting molecular abnormal-
ities (ﬁgure 3C). Each molecular abnormality is pathogenic to
a speciﬁc disease, which shares with others only the type of
protein actively sequestered as a protective mechanism. Such
protective sequestration of proteins could allow neurons to
function for decades before becoming overwhelmed, delaying
the progression of neurologic disease. In this model, targeting
soluble oligomers or ﬁbrils (e.g., using anti-aggregant thera-
pies or possibly passive or active immunotherapy) might
potentially be deleterious if the toxicity of any of the protein
species is outweighed by their protective role in the human
brain under molecular stress.
Implications for biomarkers and
clinical trials
Hypothesis 1: Biomarkers of protein
aggregates are relevant to common pathology
but not to subgroup pathogenesis
Based on the challenges discussed above, abnormal protein
aggregates (pathology) may represent downstream events,
unhelpful to classify PD and AD with pathogenic relevance.
Thus far, biomarker development eﬀorts have been based on
disease models of clinico-pathologic convergence. One such
convergence biomarker is [123I]-FP-CIT SPECT imaging for
striatal dopamine deﬁciency. It is positive in virtually everyone
with PD. Because biomarker discovery has been based on
clinically deﬁned cohorts (e.g., tremor-dominant PD vs postural
instability gait disorder type), signiﬁcant results within and
between cohorts have substantial overlap.40
Hypothesis 2: Disease-modifying treatments
targeting oligomers or fibrils might be futile or
deleterious because these proteins are
epiphenomena or protective in the human
brain under molecular stress
Targeting these proteins across sporadic or otherwise non-
genetic disease forms is unlikely to slow progression of these
disorders, nomatter how early the treatments are implemented
(i.e., prodromal stage), unless protein aggregation acts as an
accelerator of pathology, as suggested in alternative model 1.
The corollary is that applying molecular therapies aimed at
achieving neuroprotection to clinically (pathologically) de-
ﬁned, but not molecularly subtyped, populations will remain
unlikely to succeed. The history of medicine has repeatedly
shown that single (untreatable) clinical diseases are often
replaced by several (treatable) molecular diseases. As a conse-
quence, treatments designed to target speciﬁc mechanisms
work best in certain disease subtypes, but not in others.
Relinquishing reductionism (the clinically heterogeneous but
single-disease concepts for AD and PD) will require accepting
that sophisticated data analyses of large cohorts will not be
capable of identifying molecular disease subtypes, as the anal-
yses cannot overcome the fundamental ﬂaw of existent datasets:
cohorts invariably assembled based on strict clinical criteria. Big
data may not easily be converted into good data (for the pur-
poses of assisting precision medicine) if the data are based on
binary deﬁnitions of AD vs control and PD vs control. Impor-
tant insights may be derived, on a smaller scale, from studying
rare genetic forms of disease (e.g., PD-LRRK2, PD-GBA, AD-
PS1), for which targeted therapeutic eﬀorts may be most likely
to succeed—in these subtypes. On a wider scale, molecularly
targetable neurodegenerative diseases may be best identiﬁed
from population-based studies applying non-hypothesis-based
analytic approaches to biospecimens from large cohorts of aging
people, carefully characterized across a spectrum of brain
functions and deﬁcits. Thus, aging cohorts ought to include
atypical clinical presentations and other, ostensibly unrelated
neurologic disorders beyond the current criteria for PD andAD.
The analyses will need to be anchored on biological signals, not
on clinical phenotypes or clinical criteria, and account for ge-
netic and lifelong biochemical and environmental factors. Mo-
lecular subtypes of disease thus identiﬁed may or may not fall
into standard clinical classiﬁcations.
The ﬁrst proven neuroprotective therapy might only work in
fewer than 5% of everyone currently subsumed as “AD” or
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“PD” (e.g., GZ/SAR402671 in early-stage PD-GBA [Clin-
icalTrials.gov Identiﬁer: NCT02906020]) or in speciﬁc at-
risk populations (e.g., solanezumab or gantenerumab for
healthy individuals with an autosomal dominant AD-causing
mutation [Dominantly Inherited Alzheimer Network Trial;
ClinicalTrials.gov Identiﬁer: NCT01760005]). Such disease-
modifying treatment in neurodegenerative disease will help
usher in the biomarker-driven disease subtyping strategy long
adopted by oncology and other ﬁelds of medicine.
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Figure 3 Alternative models of protein aggregation in Parkinson disease (multiple disease model)
Abnormal soluble oligomers and fibrils ofα-synuclein (α-syn), while not directly pathogenic, act as accelerators of neurodegeneration (“fueling the fire”) due to
early pathogenic molecular abnormalities, each representingmolecularly distinct diseases (A, model 1). Alternatively, abnormal soluble oligomers and fibrils
of α-synuclein aggregate into Lewy bodies as byproducts of earlier pathogenic molecular mechanisms, without directly affecting the neurodegenerative
process brought on by eachmolecular disease (B,model 2). Finally, α-synuclein aggregates into Lewy bodies as amechanism to protect the neuron from toxic
protein species or from the biological dysfunction that may have generated the formation of toxic species, “cooling” progression of cell degeneration under
biological stress (C, model 3). Note that each molecularly defined disease has a different time to death; collectively, time to neuronal death is longest in
diseases corresponding to model C.
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